Drug Approval | January 14, 2022
WHO recommends two new drugs for COVID-19
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
The company will manufacture a cancer immunotherapy product from 2022
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Second interchangeable biosimilar product approved by agency
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).
Subscribe To Our Newsletter & Stay Updated
